Monitor the Precision Liver Symposium on November 4, 2026 for the actual data presentation, which may provide more detailed efficacy and safety results for DA-1726. The company's market cap is $8M, so any positive or negative data could be material, but this filing itself contains no new data.
Price Chart
Executive Summary
MetaVia Inc. announced that an abstract of Phase 1 clinical trial data for its drug candidate DA-1726 has been accepted for an oral presentation at the Precision Liver Symposium 2026 on November 4, 2026. The presentation will cover data from a randomized placebo-controlled trial showing significant reduction in MRI-PDFF and weight loss with relative preservation of lean mass. This is a routine disclosure of a scientific conference presentation with no new financial data or guidance.
Key Facts
- Abstract of Phase 1 clinical trial data for DA-1726 accepted for oral presentation at Precision Liver Symposium 2026 on November 4, 2026 in Denver, Colorado.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors.
- Presentation title: 'DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial'.
- Presenting author is Sarah Browne, M.D., Chief Medical Officer of MetaVia.
- In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction (company statement).
- No financial data, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial impact disclosed; the filing is a routine disclosure of a scientific presentation.
Risk Factors
- The filing contains forward-looking statements about DA-1726's potential, which are subject to clinical and regulatory risks.
- No actual clinical data from the Phase 1 trial was disclosed in this filing; the presentation will occur on November 4, 2026.
- Company has a history of net losses and may need additional capital to fund operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-119401 |
| Document: mtva-ex99d1.htm | 0001104659-26-119401 |
| Document: 0001104659-26-119401-index-headers.html | 0001104659-26-119401 |
| Document: 0001104659-26-119401-index.html | 0001104659-26-119401 |
| Document: 0001104659-26-119401.txt | 0001104659-26-119401 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 8-K | $1.14 | awaiting T+20 | awaiting T+20 | $1.19 (+4.39%) |
Oct 13, 2026 16d ago | 3 | $1.36 | awaiting T+20 | awaiting T+20 | $1.19 (−12.50%) |
Oct 13, 2026 16d ago | 8-K | $1.43 | awaiting T+20 | awaiting T+20 | $1.19 (−16.78%) |
Sep 9, 2026 7w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.19 (−31.61%) |
Jul 9, 2026 16w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.19 (−31.21%) |
Jul 2, 2026 17w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.19 (+19.59%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.19 (−37.04%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.19 (−46.40%) |
May 27, 2026 22w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.19 (−64.37%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.19 (+7.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers